Peptide-T

HIV Envelope Derived Peptide / NeuropeptideRx: ResearchCompound: Investigational

Also known as: ASTTTNYT, D-Ala-Peptide T-amide, DAPTA, Peptide T amide

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Peptide-T (ASTTTNYT) is an octapeptide originally identified by Candace Pert and colleagues in the 1980s as a potential anti-HIV agent. It was investigated as an antiviral and neuroprotective agent in HIV/AIDS-associated neurological complications (AIDS dementia complex). Clinical trials showed some benefit in cognitive and neurological symptoms in HIV-infected individuals, but it never achieved FDA approval. Interest has continued in its CNS effects and potential as a CCR5 antagonist.

Mechanism of Action

Peptide-T is an octapeptide derived from the V2 region of the HIV-1 gp120 envelope protein. It competitively blocks HIV gp120 binding to the CD4 receptor and CCR5 co-receptor on T-cells and neurons, and is proposed to modulate chemokine signaling (particularly CCR5/CCR2). It may also have neuroprotective effects by antagonizing gp120-mediated neurotoxicity.

Routes of Administration

IntranasalIntravenousSubcutaneous

Goals & Uses

  • PsoriasisDermatology / InflammatoryLow
  • NeuroprotectionNeurologyLow
  • Anti-HIV / blocking viral entryAntiviralLow
  • HIV-associated neurocognitive disorders (HAND) / AIDS dementia complexNeurological / AntiviralLow
  • CCR5 antagonism / anti-inflammatoryImmunologicalLow

Contraindications

  • Hypersensitivity to Peptide-T or its componentsAllergy / ImmunologicalHigh
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data

Adverse Effects

  • Injection site reactionsLocalUncommon
  • HeadacheNeurologicUncommonPain in the head or upper neck
  • FatigueGeneralUncommonLow energy or tiredness
  • Nasal irritation / rhinorrheaLocal / IntranasalCommon

Drug Interactions

  • Antiretroviral agents (e.g., CCR5 antagonists such as maraviroc)Low
  • ImmunosuppressantsLowPotential interaction with immune pathways or infection risk

Population Constraints

  • Severe renal or hepatic impairmentOrgan FunctionRelative
  • Pediatric patientsAgeRelative
  • Pregnant or breastfeeding womenReproductiveRelative

Regulatory Status

  • European UnionUnapprovedNo EMA marketing authorization. Research use only.
  • United StatesInvestigationalInvestigated under IND in Phase I/II trials (1980s–1990s) for HIV-associated neurological disease. Never approved by the FDA.
  • United KingdomUnapprovedNo MHRA approval. Research use only.

Never received FDA, EMA, or MHRA approval. Investigated in Phase I/II clinical trials in the late 1980s–1990s. Not commercially available as a licensed medicine; available only through research channels.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack